High-throughput cell-based assays for identifying antagonists of multiple smoking-associated human nicotinic acetylcholine receptor subtypes
There is substantial evidence that in addition to nicotine, other compounds found in tobacco smoke significantly influence smoking behavior. Further, recent years have seen an explosion in the availability of non-combusted products that deliver nicotine, such as e-cigarettes and “home-brew” vaping d...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-01-01
|
| Series: | SLAS Discovery |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2472555221000010 |
| _version_ | 1818756318558683136 |
|---|---|
| author | Michelle Kassner J. Brek Eaton Nanyun Tang Joachim L. Petit Nathalie Meurice Hongwei Holly Yin Paul Whiteaker |
| author_facet | Michelle Kassner J. Brek Eaton Nanyun Tang Joachim L. Petit Nathalie Meurice Hongwei Holly Yin Paul Whiteaker |
| author_sort | Michelle Kassner |
| collection | DOAJ |
| description | There is substantial evidence that in addition to nicotine, other compounds found in tobacco smoke significantly influence smoking behavior. Further, recent years have seen an explosion in the availability of non-combusted products that deliver nicotine, such as e-cigarettes and “home-brew” vaping devices that are essentially unregulated. There are many thousands of compounds in tobacco smoke alone, and new products are constantly introducing new compounds. Uncovering which of these compounds are active, across multiple smoking-relevant subtypes of the nicotinic acetylcholine receptor (nAChR) that influence tobacco/nicotine addiction, requires a high-throughput screening (HTS) approach. Accordingly, we developed a panel of HTS-friendly cell-based assays, all performed in the same cellular background and using the same membrane potential dye readout, to measure the function of the α3β4-, α4β2-, and α6β2-nAChR subtypes. These subtypes have each been prominently and consistently associated with human smoking behavior. We validated our assays by performing pilot screening of an expanded set of the Prestwick FDA-approved drug library. The screens displayed excellent performance parameters, and moderate hit rates (mean of 1.2% across all three assays) were achieved when identifying antagonists (chosen since effects of endogenous antagonists on consumption of nicotine/tobacco products are under-studied). Validation rates using an orthogonal assay (86Rb+ efflux) averaged 73% across the three assays. The resulting panel of assays represents a valuable new platform with which to screen and identify nAChR subtype-selective compounds. This provides a resource for identifying smoking-related compounds in both combusted and non-combusted tobacco products, with potential relevance in the search for additional smoking-cessation therapies. |
| first_indexed | 2024-12-18T05:53:08Z |
| format | Article |
| id | doaj.art-69bed0571f2b4e86ad58d7d3b8564877 |
| institution | Directory Open Access Journal |
| issn | 2472-5552 |
| language | English |
| last_indexed | 2024-12-18T05:53:08Z |
| publishDate | 2022-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | SLAS Discovery |
| spelling | doaj.art-69bed0571f2b4e86ad58d7d3b85648772022-12-21T21:18:52ZengElsevierSLAS Discovery2472-55522022-01-012716876High-throughput cell-based assays for identifying antagonists of multiple smoking-associated human nicotinic acetylcholine receptor subtypesMichelle Kassner0J. Brek Eaton1Nanyun Tang2Joachim L. Petit3Nathalie Meurice4Hongwei Holly Yin5Paul Whiteaker6Cancer and Cell Biology Division, Translational Genomics Research Institute, Phoenix, AZ 85004, United StatesDivision of Neurobiology, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, 350 W. Thomas Rd., Phoenix, AZ 85013, United StatesCancer and Cell Biology Division, Translational Genomics Research Institute, Phoenix, AZ 85004, United StatesDepartment of Hematology/Oncology, Mayo Clinic, Scottsdale, AZ 85259, United StatesDepartment of Hematology/Oncology, Mayo Clinic, Scottsdale, AZ 85259, United StatesCancer and Cell Biology Division, Translational Genomics Research Institute, Phoenix, AZ 85004, United States; Corresponding authors.Division of Neurobiology, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, 350 W. Thomas Rd., Phoenix, AZ 85013, United States; Corresponding authors.There is substantial evidence that in addition to nicotine, other compounds found in tobacco smoke significantly influence smoking behavior. Further, recent years have seen an explosion in the availability of non-combusted products that deliver nicotine, such as e-cigarettes and “home-brew” vaping devices that are essentially unregulated. There are many thousands of compounds in tobacco smoke alone, and new products are constantly introducing new compounds. Uncovering which of these compounds are active, across multiple smoking-relevant subtypes of the nicotinic acetylcholine receptor (nAChR) that influence tobacco/nicotine addiction, requires a high-throughput screening (HTS) approach. Accordingly, we developed a panel of HTS-friendly cell-based assays, all performed in the same cellular background and using the same membrane potential dye readout, to measure the function of the α3β4-, α4β2-, and α6β2-nAChR subtypes. These subtypes have each been prominently and consistently associated with human smoking behavior. We validated our assays by performing pilot screening of an expanded set of the Prestwick FDA-approved drug library. The screens displayed excellent performance parameters, and moderate hit rates (mean of 1.2% across all three assays) were achieved when identifying antagonists (chosen since effects of endogenous antagonists on consumption of nicotine/tobacco products are under-studied). Validation rates using an orthogonal assay (86Rb+ efflux) averaged 73% across the three assays. The resulting panel of assays represents a valuable new platform with which to screen and identify nAChR subtype-selective compounds. This provides a resource for identifying smoking-related compounds in both combusted and non-combusted tobacco products, with potential relevance in the search for additional smoking-cessation therapies.http://www.sciencedirect.com/science/article/pii/S2472555221000010Nicotinic acetylcholine receptorMembrane potential assaysCell-based screening |
| spellingShingle | Michelle Kassner J. Brek Eaton Nanyun Tang Joachim L. Petit Nathalie Meurice Hongwei Holly Yin Paul Whiteaker High-throughput cell-based assays for identifying antagonists of multiple smoking-associated human nicotinic acetylcholine receptor subtypes SLAS Discovery Nicotinic acetylcholine receptor Membrane potential assays Cell-based screening |
| title | High-throughput cell-based assays for identifying antagonists of multiple smoking-associated human nicotinic acetylcholine receptor subtypes |
| title_full | High-throughput cell-based assays for identifying antagonists of multiple smoking-associated human nicotinic acetylcholine receptor subtypes |
| title_fullStr | High-throughput cell-based assays for identifying antagonists of multiple smoking-associated human nicotinic acetylcholine receptor subtypes |
| title_full_unstemmed | High-throughput cell-based assays for identifying antagonists of multiple smoking-associated human nicotinic acetylcholine receptor subtypes |
| title_short | High-throughput cell-based assays for identifying antagonists of multiple smoking-associated human nicotinic acetylcholine receptor subtypes |
| title_sort | high throughput cell based assays for identifying antagonists of multiple smoking associated human nicotinic acetylcholine receptor subtypes |
| topic | Nicotinic acetylcholine receptor Membrane potential assays Cell-based screening |
| url | http://www.sciencedirect.com/science/article/pii/S2472555221000010 |
| work_keys_str_mv | AT michellekassner highthroughputcellbasedassaysforidentifyingantagonistsofmultiplesmokingassociatedhumannicotinicacetylcholinereceptorsubtypes AT jbrekeaton highthroughputcellbasedassaysforidentifyingantagonistsofmultiplesmokingassociatedhumannicotinicacetylcholinereceptorsubtypes AT nanyuntang highthroughputcellbasedassaysforidentifyingantagonistsofmultiplesmokingassociatedhumannicotinicacetylcholinereceptorsubtypes AT joachimlpetit highthroughputcellbasedassaysforidentifyingantagonistsofmultiplesmokingassociatedhumannicotinicacetylcholinereceptorsubtypes AT nathaliemeurice highthroughputcellbasedassaysforidentifyingantagonistsofmultiplesmokingassociatedhumannicotinicacetylcholinereceptorsubtypes AT hongweihollyyin highthroughputcellbasedassaysforidentifyingantagonistsofmultiplesmokingassociatedhumannicotinicacetylcholinereceptorsubtypes AT paulwhiteaker highthroughputcellbasedassaysforidentifyingantagonistsofmultiplesmokingassociatedhumannicotinicacetylcholinereceptorsubtypes |